NASDAQ:VKTX - Viking Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $15.38
Forecasted Upside: 152.88 %
Number of Analysts: 9
Breakdown:
0 Sell Ratings
0 Hold Ratings
9 Buy Ratings
0 Strong Buy Ratings

^$6.08 As of 06/16/2021 01:00 AM ET

▲ +0.05 (0.83%)

1 month | 3 months | 12 months

Get New Viking Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for VKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VKTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$15.38

▲ +152.88% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $15.38, with a high forecast of $21.00 and a low forecast of $12.00. The average price target represents a 152.88% upside from the last price of $6.08.

Buy

The current consensus among 9 investment analysts is to buy stock in Viking Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/24/2019

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/23/2020

0 strong buy ratings
13 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/21/2020

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/19/2020

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/18/2020

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/18/2021

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/17/2021

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/16/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
5/25/2021	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$27.00 ➝ $12.00	High	i
5/3/2021	SVB Leerink	Reiterated Rating	Buy	$18.00	High	i
1/22/2021	Stifel Nicolaus	Reiterated Rating	Buy	$13.00	Low	i Rating by Derek Archila at Stifel Nicolaus
10/29/2020	Raymond James	Boost Price Target	Strong-Buy	$25.00 ➝ $27.00	Medium	i
9/11/2020	William Blair	Reiterated Rating	Buy		Low	i Rating by Andy Hsieh at William Blair
9/10/2020	B. Riley	Reiterated Rating	Buy	$15.00	High	i Rating by Mayank Mamtani at B. Riley
9/1/2020	BTIG Research	Boost Price Target	Buy	$9.00 ➝ $12.00	High	i
8/31/2020	Chardan Capital	Boost Price Target	Buy	$15.00 ➝ $20.00	Medium	i Rating by Michael Morabito at Chardan Capital
8/28/2020	HC Wainwright	Boost Price Target	Buy	$18.00 ➝ $21.00	High	i
8/6/2020	Raymond James	Reiterated Rating	Buy	$25.00	Medium	i
7/30/2020	B. Riley	Reiterated Rating	Buy	$12.00	High	i Rating by Mayank Mamtani at B. Riley
7/29/2020	Chardan Capital	Reiterated Rating	Buy	$15.00	High	i Rating by Michael Morabito at Chardan Capital
7/29/2020	Oppenheimer	Reiterated Rating	Buy	$12.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
7/29/2020	Stifel Nicolaus	Reiterated Rating	Buy	$14.00	High	i Rating by Derek Archila at Stifel Nicolaus
6/4/2020	BMO Capital Markets	Initiated Coverage	Outperform	$14.00	Medium	i
5/5/2020	Chardan Capital	Initiated Coverage	Buy	$15.00	Medium	i Rating by M. Morabito at Chardan Capital
5/4/2020	B. Riley	Lower Price Target	Buy	$16.00 ➝ $12.00	High	i Rating by Mayank Mamtani at B. Riley
5/2/2020	Maxim Group	Initiated Coverage	Buy	$14.00	High	i Rating by Jason McCarthy at Maxim Group
5/1/2020	Oppenheimer	Initiated Coverage	Buy	$12.00	High	i Rating by Jay Olson at Oppenheimer Holdings Inc.
5/1/2020	Raymond James	Lower Price Target	Strong-Buy	$41.00 ➝ $25.00	High	i
5/1/2020	BTIG Research	Initiated Coverage	Buy	$9.00	High	i
4/30/2020	Stifel Nicolaus	Reiterated Rating	Buy	$14.00	High	i
4/3/2020	William Blair	Reiterated Rating	Buy		Low	i Rating by Andy Hsieh at William Blair
3/18/2020	William Blair	Reiterated Rating	Buy		High	i Rating by Andy Hsieh at William Blair
2/27/2020	HC Wainwright	Lower Price Target	Buy	$31.00 ➝ $18.00	High	i
1/2/2020	SVB Leerink	Reiterated Rating	Outperform		Medium	i Rating by T. Smith at SVB Leerink LLC
11/21/2019	B. Riley	Initiated Coverage	Buy	$16.00	Low	i Rating by Mayank Mamtani at B. Riley
11/6/2019	Maxim Group	Reiterated Rating	Buy	$14.00	Low	i
11/5/2019	HC Wainwright	Reiterated Rating	Buy	$31.00	High	i
8/2/2019	HC Wainwright	Reiterated Rating	Buy	$31.00	High	i Rating by J. Pantginis at HC Wainwright
7/16/2019	CIBC	Initiated Coverage	Outperform ➝ Outperform	$12.00	Low	i
7/16/2019	Oppenheimer	Initiated Coverage	Outperform	$12.00 ➝ $12.00	High	i
7/15/2019	Citigroup	Initiated Coverage	Outperform		High	i
6/25/2019	Stifel Nicolaus	Initiated Coverage	Buy ➝ Buy	$14.00	High	i
4/11/2019	HC Wainwright	Reiterated Rating	Buy	$31.00	Medium	i Rating by Joseph Pantginis at HC Wainwright
3/29/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$10.00 ➝ $21.00	High	i Rating by P. Sarraf at SVB Leerink LLC
3/29/2019	William Blair	Reiterated Rating	Outperform		High	i Rating by Andy Hsieh at William Blair
3/14/2019	Raymond James	Lower Price Target	Strong-Buy ➝ Strong-Buy	$43.00 ➝ $40.00	Low	i Rating by Steven Seedhouse at Raymond James
3/14/2019	William Blair	Reiterated Rating	Outperform		High	i Rating by Andy Hsieh at William Blair
3/14/2019	Maxim Group	Lower Price Target	Buy	$28.00 ➝ $20.00	High	i
2/22/2019	SVB Leerink	Initiated Coverage	Market Perform	$10.00	Medium	i
12/11/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$16.00	Low	i Rating by Mayank Mamtani at B. Riley
11/19/2018	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$43.00	High	i Rating by Steven Seedhouse at Raymond James
11/13/2018	William Blair	Reiterated Rating	Buy		High	i Rating by Andy Hsieh at William Blair
11/9/2018	Roth Capital	Set Price Target	Buy	$23.00	Medium	i Rating by Scott Henry at Roth Capital
11/8/2018	Maxim Group	Reiterated Rating	Buy	$28.00	High	i
11/8/2018	HC Wainwright	Reiterated Rating	Buy	$31.00	N/A	i Rating by Joseph Pantginis at HC Wainwright
10/1/2018	William Blair	Reiterated Rating	Market Perform		High	i Rating by A. Hsieh at William Blair
10/1/2018	HC Wainwright	Set Price Target	Buy	$31.00	High	i Rating by Joseph Pantginis at HC Wainwright
9/19/2018	Raymond James	Set Price Target	Buy	$43.00	Low	i Rating by Steven Seedhouse at Raymond James
9/19/2018	Roth Capital	Boost Price Target	Buy	$13.00 ➝ $24.00	High	i
9/19/2018	SunTrust Banks	Boost Price Target	Buy	$28.00	High	i
9/18/2018	Maxim Group	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $28.00	High	i Rating by Jason McCarthy at Maxim Group
9/18/2018	Raymond James	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $43.00	High	i Rating by Steven Seedhouse at Raymond James
9/18/2018	HC Wainwright	Set Price Target	Buy ➝ Buy	$15.00 ➝ $28.00	High	i Rating by Joseph Pantginis at HC Wainwright
8/10/2018	William Blair	Reiterated Rating	Outperform		High	i Rating by A. Hsieh at William Blair
8/10/2018	HC Wainwright	Reiterated Rating	Buy	$15.00	High	i Rating by Joseph Pantginis at HC Wainwright
7/20/2018	SunTrust Banks	Initiated Coverage	Buy	$14.00	High	i
6/28/2018	Raymond James	Initiated Coverage	Outperform	$15.00	Medium	i
6/1/2018	Roth Capital	Boost Price Target	Buy	$7.50 ➝ $13.00	Low	i Rating by Scott Henry at Roth Capital
6/1/2018	Laidlaw	Boost Price Target	Buy	$10.00 ➝ $15.00	High	i
6/1/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $15.00	High	i Rating by Joseph Pantginis at HC Wainwright
5/31/2018	Maxim Group	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $14.00	High	i Rating by Jason McCarthy at Maxim Group
5/10/2018	HC Wainwright	Set Price Target	Buy	$11.00	High	i Rating by Joseph Pantginis at HC Wainwright
5/10/2018	Maxim Group	Set Price Target	Buy	$8.00	High	i Rating by Jason McCarthy at Maxim Group
4/30/2018	William Blair	Initiated Coverage	Outperform		Low	i Rating by A. Hsieh at William Blair
3/26/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$11.00	High	i Rating by Joseph Pantginis at HC Wainwright
3/8/2018	Roth Capital	Set Price Target	Buy	$8.00	High	i Rating by Scott Henry at Roth Capital
3/8/2018	Maxim Group	Reiterated Rating	Buy	$8.00	High	i Rating by Jason McCarthy at Maxim Group
2/2/2018	Maxim Group	Reiterated Rating	Buy	$8.00	Low	i Rating by Jason McCarthy at Maxim Group
12/12/2017	Maxim Group	Set Price Target	Buy	$8.00	Low	i Rating by Jason McCarthy at Maxim Group
11/29/2017	Roth Capital	Set Price Target	Buy	$6.00	High	i Rating by Scott Henry at Roth Capital
11/28/2017	Maxim Group	Set Price Target	Buy	$5.00 ➝ $8.00	High	i Rating by Jason McCarthy at Maxim Group
11/21/2017	Roth Capital	Initiated Coverage	Buy ➝ Buy	$5.00	N/A	i Rating by S. Henry at Roth Capital
11/10/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$7.00	N/A	i Rating by E. Arce at HC Wainwright
10/4/2017	Maxim Group	Reiterated Rating	Buy	$5.00	N/A	i Rating by Jason McCarthy at Maxim Group
9/11/2017	Maxim Group	Reiterated Rating	Buy	$5.00	High	i Rating by Jason McCarthy at Maxim Group
8/10/2017	Maxim Group	Set Price Target	Buy	$5.00	High	i Rating by Jason McCarthy at Maxim Group
7/17/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $7.00	Low	i
6/6/2017	Maxim Group	Set Price Target	Buy	$5.00	Low	i Rating by Jason McCarthy at Maxim Group
5/11/2017	Maxim Group	Reiterated Rating	Buy	$5.00	High	i Rating by Jason McCarthy at Maxim Group
3/27/2017	HC Wainwright	Reiterated Rating	Buy	$5.00	Medium	i
3/22/2017	Maxim Group	Set Price Target	Buy	$5.00	Medium	i Rating by Jason McCarthy at Maxim Group
2/11/2017	Maxim Group	Set Price Target	Buy	$5.00	N/A	i Rating by Jason McCarthy at Maxim Group
12/7/2016	Maxim Group	Set Price Target	Buy	$5.00	N/A	i Rating by Jason McCarthy at Maxim Group
11/11/2016	Maxim Group	Set Price Target	Buy	$5.00	N/A	i Rating by Jason McCarthy at Maxim Group
10/25/2016	Maxim Group	Set Price Target	Buy	$5.00	N/A	i Rating by Jason McCarthy at Maxim Group
9/18/2016	HC Wainwright	Reiterated Rating	Buy	$6.00	N/A	i Rating by Carol Werther at HC Wainwright
8/11/2016	Maxim Group	Set Price Target	Buy	$5.00	N/A	i Rating by jason mccarthy at Maxim Group
8/11/2016	Laidlaw	Lower Price Target	Buy	$20.00 ➝ $10.00	N/A	i

(Data available from 6/16/2016 forward)

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $6.08

$5.86

$6.08

50 Day Range

MA: $5.84

$5.19

$6.39

52 Week Range

Now: $6.08

$4.95

$10.09

Volume

817,794 shs

Average Volume

1,213,466 shs

Market Capitalization

$474.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Viking Therapeutics?

The following Wall Street sell-side analysts have issued reports on Viking Therapeutics in the last twelve months: B. Riley, BTIG Research, Chardan Capital, HC Wainwright, Oppenheimer Holdings Inc., Raymond James, Stifel Nicolaus, SVB Leerink LLC, William Blair, and Zacks Investment Research.
View the latest analyst ratings for VKTX.

What is the current price target for Viking Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Viking Therapeutics in the last year. Their average twelve-month price target is $15.38, suggesting a possible upside of 152.9%. HC Wainwright has the highest price target set, predicting VKTX will reach $21.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $12.00 for Viking Therapeutics in the next year.
View the latest price targets for VKTX.

What is the current consensus analyst rating for Viking Therapeutics?

Viking Therapeutics currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VKTX will outperform the market and that investors should add to their positions of Viking Therapeutics.
View the latest ratings for VKTX.

What other companies compete with Viking Therapeutics?

Other companies that are similar to Viking Therapeutics include Ironwood Pharmaceuticals, Protagonist Therapeutics, Seres Therapeutics, Harmony Biosciences, Supernus Pharmaceuticals, Madrigal Pharmaceuticals, Zymeworks, Amneal Pharmaceuticals, Cerevel Therapeutics, Arcus Biosciences, Aurinia Pharmaceuticals, Constellation Pharmaceuticals, Heron Therapeutics, Indivior and ADC Therapeutics.

How do I contact Viking Therapeutics' investor relations team?

Viking Therapeutics' physical mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company's listed phone number is 858-704-4660 and its investor relations email address is [email protected] The official website for Viking Therapeutics is www.vikingtherapeutics.com.